BG Medicine, Inc.

Abbott to Develop New Heart Failure Test on ARCHITECT® Immunochemistry Diagnostics Platform

Abbott to Develop New Heart Failure Test on ARCHITECT® Immunochemistry Diagnostics Platform

November 17, 2009

ABBOTT PARK, Ill. and WALTHAM, MA., November 17, 2009 — Abbott (NYSE: ABT) and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott’s Architect immunochemistry instrument platform, specifically the company’s i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine’s intellectual property related to galectin-3. Financial terms were not disclosed.

Receptos, Inc.

Receptos Completes $25M Series A Financing

Receptos Completes $25M Series A Financing

November 23, 2009

Experienced Drug Hunters Armed with Structure-Based G Protein-Coupled Receptor (GPCR) Drug Discovery Technology From The Scripps Research Institute

VisEn Medical, Inc.

VisEn Launches New Osteosense® 800 and Vivotag® 800 Fluorescence Molecular Imaging Agents

VisEn Launches New Osteosense® 800 and Vivotag® 800 Fluorescence Molecular Imaging Agents

November 19, 2009

Expands VisEn’s Fluorescence Molecular Imaging Agent Portfolio to Enable Enhanced Multiplexed Readouts of Key Biomarkers in Research and Drug Development

Acceleron Pharma, Inc.

Acceleron Pharma Presents Findings of ACE-536, a Novel Red Blood Cell-Forming Agent, at the 51st Annual Meeting of the American Society of Hematology

Acceleron Pharma Presents Findings of ACE-536, a Novel Red Blood Cell-Forming Agent, at the 51st Annual Meeting of the American Society of Hematology

December 8, 2009

Company Discovers Novel Mechanism to Increase Red Blood Cells

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 8, 2009 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Meeting of the American Society of Hematology.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Broadens Management Team and Expands Product Advisory Board

Concert Pharmaceuticals Broadens Management Team and Expands Product Advisory Board

December 9, 2009

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. announced today the appointment of Lijun Wu, Ph.D., as Vice President, Biology. In this newly created position, Dr. Wu will have responsibility for Concert’s non-clinical pharmacology, pharmacokinetics, drug metabolism, and bioanalytical functions and will report to Roger Tung, Ph.D., President and Chief Executive Officer of Concert.

Novomer, Inc.

Novomer Expands Green Materials Commercialization With Kodak, RIT and NYSERDA

Novomer Expands Green Materials Commercialization With Kodak, RIT and NYSERDA

December 14, 2009

$800,000 New York State Funding Set to Create Green Jobs, Increase Manufacturing and Reduce Dependency on Petroleum-Based Plastics

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Files Registration Statement for Initial Public Offering

AVEO Pharmaceuticals Files Registration Statement for Initial Public Offering

December 16, 2009

CAMBRIDGE, Mass., December 16, 2009—AVEO Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

Acceleron Pharma, Inc.

Acceleron Pharma Expands Management Team with Two New Appointments

Acceleron Pharma Expands Management Team with Two New Appointments

December 22, 2009

Key Personnel Support Growth and Advancement of Clinical Pipeline and GMP Manufacturing Activities

Novomer, Inc.

Novomer highlighted as #1 in GreanBeat's 2009’s top 9 forward-looking cleantech investments

Novomer highlighted as #1 in GreanBeat's 2009’s top 9 forward-looking cleantech investments

December 31, 2009

1. Novomer — In April, Novomer, a company that sequesters carbon dioxide emissions from coal-fired plants and other sources in biodegradable plastic consumer products, brought in $14 million ... has the opportunity to capture a vast amount of carbon that would otherwise be released into the atmosphere while cheaply making plastic products that don’t require as much petroleum. It’s basically greening two businesses at once.

T2 Biosystems, Inc.

T2 BioSystems Appoints Ken Toso Vice President, Product Development

T2 BioSystems Appoints Ken Toso Vice President, Product Development

January 6, 2010

Company Preparing for Commercial Evaluation and Launch